Small Cap Losers: BTCM, BTX, CGEM
3:23 pm Friday, May 21st, 2021
BIT Mining Ltd – ADR (NYSE:BTCM): Extends recent pullback amid continued volatility in the cryptocurrency space; sharp selling action in various cryptocurrencies followed further reports that China intends to crack down on bitcoin mining and trading. The stock is down by 21.22% to $9.91.
BIT Mining Limited operates as a cryptocurrency mining company. It holds three hydroelectric cryptocurrency mines with combined electric power capacity of 435MW; and mining pool business, including the domain name and the cryptocurrency wallet of BTC.com, as well as purchases and deploys bitcoin mining machines.
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN:BTX): The stock continues to pare the spike that it recorded in late April, now trading lower by approx. 70% month-to-date. In recent press, co today announced that Michael Andreeff, M.D., Ph.D. has been appointed to co’s Scientific Advisory Board. The stock is down 12.50% to $14.51.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Cullinan Oncology Inc (NASDAQ: CGEM): Touches down to new 52-week lows. In recent press, co today announced that Jon Wigginton, M.D. will step down from his day-to-day role as co’s Chief Medical Officer and assume the role of Chairman of co’s Scientific Advisory Board and Senior Advisor to the CEO. At the time of writing, CGEM stock slumped 10.40% at $27.25.
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company’s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
